Michael Mitchell, an associate professor of bioengineering at the University, is developing novel lipid nanoparticles that can deliver mRNA inside human cells, which could pave the way for therapies ...

BERLIN--(BUSINESS WIRE)--Bayer AG is joining forces with Acuitas Therapeutics, Inc., a biotechnology company specializing in the development of lipid nanoparticle (LNP) delivery systems for molecular ...

Six years before the pandemic, fledgling Cambridge biotech Moderna was searching for a way to get its revolutionary RNA technology to work in humans. One of the biggest problems was figuring out how ...

Certest Pharma specializes in advanced lipid nanoparticle technology, focusing on the development of effective and targeted LNPs for next-generation medicines. Certest’s licensable technology includes ...

Under Leshem's leadership, ViVac will accelerate its preclinical oncology pipeline, which includes programs in liver, ovarian and other solid tumors — indications representing significant unmet needs ...

Partner Dan Shores will present a webinar titled "The mRNA/Lipid Nanoparticle Competitive and Litigation Landscape" for Medmarc, the leading expert in the products liability risks facing medical ...

Although chimeric antigen receptor (CAR) T-cell therapies have shown encouraging results for treating hematological cancers such as leukemias and lymphomas, their success in solid tumors has so far ...